Massive study mines insurance records to see which diabetes drug protects hearts better
NCT ID NCT06779929
First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 24 times
Summary
This study looked at insurance claims from 70,000 people with type 2 diabetes and heart disease to compare two drugs, tirzepatide and dulaglutide, on their risk of heart attack, stroke, or death. The goal was to see if real-world data could mimic a large clinical trial. No new treatments were given; researchers simply analyzed existing records.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.